Allison Betof Warner, MD, PhD
LightNews LightNews
drbetofmdphd.bsky.social
Allison Betof Warner, MD, PhD
@drbetofmdphd.bsky.social
370 followers 200 following 9 posts
Director of Advanced Melanoma Program, Director of Solid Tumor Cell Therapy @StanfordCancer | @MGH Medicine/ @MSKCC Onc Alum | wife/dog mom🐾 | Philadelphia sports phanatic | CF-L2
Posts Replies Media Videos
Reposted by Allison Betof Warner, MD, PhD
sitcancer.bsky.social
New Journal for ImmunoTherapy of Cancer (JITC) commentary: Role of high-dose interleukin-2 for melanoma in the age of cellular therapy bit.ly/4jwhLmm
@drbetofmdphd.bsky.social #JITC #research #cancer 🧪
New Journal for ImmunoTherapy of Cancer (JITC) commentary: Role of high-dose interleukin-2 for melanoma in the age of cellular therapy https://bit.ly/4jwhLmm @drbetofmdphd.bsky.social #JITC #research #cancer
June 6, 2025 at 1:56 PM
Reposted by Allison Betof Warner, MD, PhD
funchainmd.bsky.social
Melanoma rapid oral #9 ➡️ OBX-115, engineered TIL with membrane bound IL15 regulated with acetazolamide

-for 6pt receiving RP2D, 67% ORR, 1 CR, 100% DCR
-mDOR not reached

Jason Chesney U Louisville and @drbetofmdphd.bsky.social @stanford-cancer.bsky.social

#ASCO25 @ascocancer.bsky.social
June 2, 2025 at 4:19 PM
drbetofmdphd.bsky.social
An entire day for solid tumor at #iwCART25! How far we’ve come in solid tumor cell therapy- 2 approvals since I was at this meeting last year! Looking forward to a great meeting.
April 11, 2025 at 12:41 PM
Reposted by Allison Betof Warner, MD, PhD
funchainmd.bsky.social
Pushing through boundaries in solid tumor cell therapy @stanford-cancer.bsky.social 📈
➡️ only 1 of 10 centers that offers sarcoma TCR-T
➡️ 50% DCR with TIL in melanoma brain mets and promising safety signal, no seizures or hemorrhages 🤞🙏 @drbetofmdphd.bsky.social @stevenartandi.bsky.social
March 25, 2025 at 11:25 PM
Reposted by Allison Betof Warner, MD, PhD
jasonlukemd.bsky.social
Enjoyed discussing LAG3 targeting #melanoma w
@drbetofmdphd.bsky.social Major role for relatlimab while fianlimab data look as good/better so far! Field has been waiting long time for RELA-098 but Ph3 studies abound for cemi-fian metastatic, adjuvant and peri-op!
www.medscape.org/viewarticle/...
February 14, 2025 at 1:15 PM
Reposted by Allison Betof Warner, MD, PhD
funchainmd.bsky.social
Fantastic panel moderated by @drbetofmdphd.bsky.social - so many melanoma trials open/opening in the Bay Area. Great company, great colleagues, and great movement to make melanoma outcomes better here in the Bay Area, and everywhere 🖤 Thanks to ANCO for continuing to elevate oncology in NoCal ⛰️
drbetofmdphd.bsky.social Allison Betof Warner, MD, PhD @drbetofmdphd.bsky.social · Feb 1
What a great Melanoma & Developmental Therapeutics Session at the @ANCO_News conference! We discussed breakthroughs from 2024 and covered exciting new trial opportunities available in the Bay Area. What a team! 🤩 @funchainmd.bsky.social
February 3, 2025 at 7:56 PM
drbetofmdphd.bsky.social
What a great Melanoma & Developmental Therapeutics Session at the @ANCO_News conference! We discussed breakthroughs from 2024 and covered exciting new trial opportunities available in the Bay Area. What a team! 🤩 @funchainmd.bsky.social
February 1, 2025 at 5:15 AM
drbetofmdphd.bsky.social
Another landmark day for solid tumor cell therapy at @stanforduniversity.bsky.social Cancer Institute with our first infusion of FDA approved afami-cel (Tecelra), an engineered TCR T cell for synovial #sarcoma. We are thrilled to make this available to our patients!! #medsky #oncsky
January 13, 2025 at 11:59 PM
Reposted by Allison Betof Warner, MD, PhD
funchainmd.bsky.social
New year, new adventures at #MedSky - oncology faculty opening for solid tumor cell therapy position 🧫@stanforduniversity.bsky.social, with preference for TIL/melanoma experience. Please contact me or @drbetofmdphd.bsky.social for more details!
drbetofmdphd.bsky.social Allison Betof Warner, MD, PhD @drbetofmdphd.bsky.social · Dec 19
SOLID TUMOR CELL THERAPY position at Stanford. We are searching for a clinical investigator (MD, MD/PhD, or equiv) with expertise in solid tumor cell therapy, preference for experience with melanoma/TILs to join our growing team!

facultypositions.stanford.edu/en-us/job/49...
Stanford | Faculty Positions: Details - Assistant or Associate Professor, Solid Tumor Cell Therapy
facultypositions.stanford.edu
January 13, 2025 at 11:28 PM
Reposted by Allison Betof Warner, MD, PhD
oncodaily.bsky.social
Cell Therapies in Sarcomas: Lete-cel in Synovial Sarcoma and MRCLs

oncodaily.com/dialogues/sa...

#Cancer #OncoDaily #Oncology #Medicine #Health
Cell Therapies in Sarcomas: Lete-cel in Synovial Sarcoma and MRCLs - OncoDaily
Cell Therapies in Sarcomas: Lete-cel in Synovial Sarcoma and MRCLs / Amalya Sargsyan, cancer, OncoDaily, Oncology, Sandra D'Angelo
oncodaily.com
January 13, 2025 at 6:08 PM
Reposted by Allison Betof Warner, MD, PhD
drmiguelperales.bsky.social
At the White House Cell and Gene Therapy Forum with my former @mskcancercenter.bsky.social colleague Kamal Menghrajani #cancermoonshot #whitehousecgt #genetherapy #CARTcells
January 8, 2025 at 6:42 PM
Reposted by Allison Betof Warner, MD, PhD
drmiguelperales.bsky.social
Merry Christmas from @mskcancercenter.bsky.social 🎅🎄
December 24, 2024 at 9:37 PM
Reposted by Allison Betof Warner, MD, PhD
oncodaily.bsky.social
A Breakthrough Year for T Cells - Nicholas Restifo

oncodaily.com/blog/nichola...

#Cancer #CARTTherapy #Immunotherapy #Nature #OncoDaily #Oncology #Medicine #Health
Nicholas Restifo: A Breakthrough Year for T Cells - OncoDaily
Nicholas Restifo: A Breakthrough Year for T Cells / cancer, CAR-T therapy, immunotherapy, Nature, Nicholas Restifo, OncoDaily, Oncology
oncodaily.com
December 22, 2024 at 4:54 PM
drbetofmdphd.bsky.social
SOLID TUMOR CELL THERAPY position at Stanford. We are searching for a clinical investigator (MD, MD/PhD, or equiv) with expertise in solid tumor cell therapy, preference for experience with melanoma/TILs to join our growing team!

facultypositions.stanford.edu/en-us/job/49...
Stanford | Faculty Positions: Details - Assistant or Associate Professor, Solid Tumor Cell Therapy
facultypositions.stanford.edu
December 19, 2024 at 10:28 PM
drbetofmdphd.bsky.social
As an alum of @mskcancercenter.bsky.social, this brings back some really warm memories. The holiday hallway is such a labor of love which is emblematic of the best of MSK!

www.instagram.com/reel/DDrsAab...
Login • Instagram
Welcome back to Instagram. Sign in to check out what your friends, family & interests have been capturing & sharing around the world.
www.instagram.com
December 17, 2024 at 3:59 PM
Reposted by Allison Betof Warner, MD, PhD
stephenvliu.bsky.social
Development of two next gen IO molecules has been discontinued. Vibostolimab (anti #TIGIT) and favezelimab (anti LAG3) programs both being shuttered. Development in this space has been significantly hampered by the lack of predictive biomarkers.

www.merck.com/news/merck-p...
Merck Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations with Pembrolizumab - Merck.com
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the discontinuation of the clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezeli...
www.merck.com
December 16, 2024 at 10:44 PM
drbetofmdphd.bsky.social
Wishing you happy and HEALTHY holidays from our @stanforduniversity.bsky.social Melanoma Oncology clinical and research team. We had a very festive celebration (including a grinch sighting!). We’ve grown tremendously over the last year- can’t wait for what’s in store for 2025!
December 13, 2024 at 6:54 AM
Reposted by Allison Betof Warner, MD, PhD
drjonlim.bsky.social
📚 In conjunction with #ESMOImmuno24, we had our annual #ESMO #IOTECH Editorial Board meeting today - delighted to see many more academics now here 🦋.

🎯 EiC: @haanenjohn.bsky.social

Section Editors:
@michalbassani.bsky.social (NeoAg/TILs)
@danielathommen.bsky.social (Biomarkers/novel IO targets)...
drjonlim.bsky.social Jon Lim, MRCP PhD @drjonlim.bsky.social · Dec 11
Gutted not to be Geneva 🇨🇭 for #ESMOImmuno24 in person this year 🥹.

If you are presenting your work at #ESMOImmuno24, and potentially looking for a home for your research work, please consider submitting to our ESMO IOTECH journal:
🔗 esmoiotech.org
December 12, 2024 at 7:30 PM
Reposted by Allison Betof Warner, MD, PhD
drjonlim.bsky.social
...and more of our amazing #ESMO #IOTECH Editorial Board members:
@drbetofmdphd.bsky.social
@dgfeller.bsky.social
@kevlitchfield.bsky.social
@artkrieg.bsky.social
@bertrandrouty.bsky.social
@charlesswanton.bsky.social
@pamsharmamdphd.bsky.social

🦋 Follow for insights into #CancerImmunology!
December 12, 2024 at 7:30 PM
Reposted by Allison Betof Warner, MD, PhD
melanomaresearch.bsky.social
From our recent webinar, Dr. Evan Lipson shares essential questions every melanoma patient should ask after their diagnosis about testing and treatment options. Empower yourself with knowledge and follow MRA to stay informed! #MelanomaAwareness
December 11, 2024 at 10:08 PM
Reposted by Allison Betof Warner, MD, PhD
scinews.bsky.social
Mannose metabolism reshapes T cell differentiation to enhance anti-tumor immunity #CancerCell

"Cell-intrinsic mannose metabolism is a physiological regulator of CD8+ T cell fate, decoupling proliferation/expansion from differentiation"

www.cell.com/cancer-cell/...
December 9, 2024 at 2:29 PM
Reposted by Allison Betof Warner, MD, PhD
rongfan8.bsky.social
SPATIAL PROTEOMICS is the Method of the Year 2024!!! 🤩🤩🤩

www.nature.com/articles/s41...
Method of the Year 2024: spatial proteomics - Nature Methods
Approaches for profiling the spatial proteome in tissues are the basis of atlas-scale projects that are delivering on their promise for understanding biological complexity in health and disease.
www.nature.com
December 7, 2024 at 12:17 AM
Reposted by Allison Betof Warner, MD, PhD
patrickhwumd.bsky.social
#ScienceSaturday

➡️ Did you know that some chemotherapies can enhance the immune response against #cancer?

❓ How might we potentiate this?
December 7, 2024 at 4:32 PM
Reposted by Allison Betof Warner, MD, PhD
scinews.bsky.social
Ageing of stem cells reduces their capacity to form tumours #Nature @natureportfolio.bsky.social

"Most human cancers initiate at a young age, highlighting the importance of directing cancer prevention efforts towards young individuals."

www.nature.com/articles/s41...
Ageing limits stemness and tumorigenesis by reprogramming iron homeostasis - Nature
Studies using mouse models of lung adenocarcinoma identify an association between age, iron homeostasis and tumour initiation potential that involves NUPR1 and lipocalin-2.
www.nature.com
December 7, 2024 at 2:51 PM
drbetofmdphd.bsky.social
Traveling home from the 2024 #ImmunotherapyBridge and #MelanomaBridge meetings in Napoli. We ate/drank ALL the food/wine, we debated, we collaborated, and we strengthened our community. I even got to debate one of my #she-roes @chrystalpaulos.bsky.social. Every year this meeting gets better!
December 8, 2024 at 7:24 PM